Skip to Content

Imlygic (talimogene laherparepvec) Disease Interactions

There are 4 disease interactions with Imlygic (talimogene laherparepvec):

Major

Talimogene Laherparepvec (Includes Imlygic) ↔ Immunocompromised

Severe Potential Hazard, Moderate plausibility

Applies to: Immunodeficiency

Talimogene laherparepvec is a live, attenuated herpes simplex virus. The use talimogene laherparepvec is contraindicated in patients who are immunocompromised as its administration in these patients may cause life-threatening disseminated herpetic infection.

Major

Talimogene Laherparepvec (Includes Imlygic) ↔ Immunodeficiency

Severe Potential Hazard, Moderate plausibility

Applies to: Immunodeficiency

Talimogene laherparepvec is a live, attenuated herpes simplex virus. Its use is contraindicated in immunocompromised patients as they may be at risk of life-threatening disseminated herpetic infection. Do not administer talimogene laherparepvec to immunocompromised patients, including those with a history of primary or acquired immunodeficient states, leukemia, lymphoma, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy.

Moderate

Talimogene Laherparepvec (Includes Imlygic) ↔ Autoimmune Disorders

Moderate Potential Hazard, Moderate plausibility

Applies to: Autoimmune Disorder

The use of talimogene laherparepvec may result in immune-mediated events. Exercise care when using this agent in patients with underlying autoimmune disease or before continuing treatment in those patients that have developed immune-mediated events. Close monitoring is recommended.

Moderate

Talimogene Laherparepvec (Includes Imlygic) ↔ Multiple Myeloma

Moderate Potential Hazard, Moderate plausibility

Applies to: Multiple Myeloma

Plasmacytoma, in proximity to the injection site, has been reported after administration of talimogene laherparepvec in a patient with smoldering multiple myeloma. It is recommended to consider the risks and benefits of treatment in patients with multiple myeloma or in whom plasmacytoma develops during treatment. Close monitoring is recommended.

Imlygic (talimogene laherparepvec) drug Interactions

There are 188 drug interactions with Imlygic (talimogene laherparepvec)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide